

Ami B Patel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4968886/publications.pdf>

Version: 2024-02-01

13
papers

262
citations

1307594

7
h-index

1281871

11
g-index

14
all docs

14
docs citations

14
times ranked

560
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic complexity of chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1031-1045.	1.3	4
2	SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2021, 2, 266-287.	5.0	37
3	A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with Myelofibrosis Refractory or Intolerant to JAK Inhibitors. <i>Blood</i> , 2021, 138, 143-143.	1.4	5
4	Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. <i>Leukemia</i> , 2020, 34, 2981-2991.	7.2	8
5	BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia. <i>Experimental Hematology</i> , 2019, 77, 36-40.e2.	0.4	14
6	Lysozyme nephropathy in chronic myelomonocytic leukemia. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 1263-1264.	0.5	10
7	JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. <i>Blood</i> , 2019, 134, 2388-2398.	1.4	25
8	Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations. <i>Blood Advances</i> , 2019, 3, 952-955.	5.2	8
9	Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib. <i>Oncotarget</i> , 2018, 9, 17889-17894.	1.8	1
10	Combining Dasatinib and AC220 Reduces Stroma-Based pSTAT5Y694 in FLT3-ITD+ AML and Overcomes FLT3 TKI Resistance. <i>Blood</i> , 2018, 132, 2641-2641.	1.4	0
11	Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 589-612.	2.2	125
12	Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. <i>ChemMedChem</i> , 2016, 11, 850-861.	3.2	23
13	Paraneoplastic opsoclonus associated with squamous cell carcinoma of the tongue. <i>Clinical Neurology and Neurosurgery</i> , 2016, 149, 11-14.	1.4	2